alexa Scholarly Journals In Lung Cancer Biomarkers |OMICS International|Journal Of Molecular Biomarkers And Diagnosis

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Scholarly Journals In Lung Cancer Biomarkers

Scholarly journals are generally academic journals that encourage academic and scientific research. These journals generally prefer to publish original works, conducted following a systematic research methodology. The articles published in the scholarly journals are critically evaluated following in-depth analysis of the research data. Scholarly Journal articles strictly adhere to a standard format of writing. Once the author accomplishes their task of writing following the standard format and submits the manuscript for publication, it is the responsibility of the scholarly journal to verify whether it is written as per the academic and research norms. Scholarly journals hence subject like medical and clinical articles for a blind peer review or double peer review system and expect the authors to correct and resubmit the research articles as per the expert opinion. Scholarly journals thus expect the authors to sign the declaration, stating that the work is original and unpublished that duly acknowledges the sources referred for information. Lung cancer is the most common cause of cancer mortality worldwide, accounting for 25% of all cancer deaths with an incidence rate of 1.2 million people per year. The main risk factor of lung cancer is smoking; the risk of lung cancer is tenfold higher in smokers than in non-smokers. Lung cancer can typically be grouped into two large categories: small-cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which account for 15% and 85% of lung cancers, respectively. NSCLC consists of 3 major histological subtypes: Adenocarcinoma (ADC), Squamous Cell Lung Carcinoma (SQLC), and Large Cell Carcinoma (LCC). A better diagnostic measure for lung cancer that facilitates the early detection of the disease, therefore allowing for effective intervention, is necessary to lower lung cancer mortality rates. The discovery of cancer biomarkers, specific molecules that help to distinguish between normal and cancerous conditions, may potentially be used to develop a more effective diagnostic tool for lung cancer. Cancer biomarkers consist of either of genetic materials or proteins because cancer is a heterogeneous disease that reflects gene and protein changes within a cancer cell. However, proteins are the main functional units of biological processes. Almost all of the Food and Drug Administration (FDA)-approved cancer biomarkers are protein markers. Proteomics is a powerful tool for identifying lung cancer biomarkers that can be tested in the blood. Several potential lung cancer biomarkers, including plasma kallikrein (KLKB1) protein fragments, serum amyloid A (SAA), haptoglobin β chain [Hp β], and complement component 9 (C9), using proteomics approaches. Lung cancer biomarkers, we have found that many protein/peptide biomarkers discovered in the serum and/or plasma seem to overlap with other diseases, especially other cancers and inflammatory diseases. Thus, the discovery of more lung tissue-specific biomarkers is needed, starting with tissue-specific genes/proteins and the related proteins in lung tissues and lung cancers. (Je-Yoel Cho, Current Serum Lung Cancer Biomarkers)
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on July, 2014

Top